title: [New trends in antimicrobial therapy of chronic purulent mesotympanitis].
abstract: Antibiotic therapy with colbiocin of chronic purulent mesotympanitis achieved a response rate of 92%, recurrence-free interval reached 6 months in 84% of the treated patients. This allows to recommend colbiocin as a drug of choice in hospital and outpatient treatment of chronic purulent mesotympanitis.
authors.forename: B M
authors.initials: BM
authors.lastname: Tsetsarskiĭ
authors.forename: A E
authors.initials: AE
authors.lastname: Mikhalashvili
authors.forename: N V
authors.initials: NV
authors.lastname: Makhlinovskaia
authors.forename: V I
authors.initials: VI
authors.lastname: Koshel'
authors.forename: A A
authors.initials: AA
authors.lastname: Faians
authors.forename: F S
authors.initials: FS
authors.lastname: Semenova
mesh_terms: D002701:Chloramphenicol / Q000627:therapeutic use*; D002908:Chronic Disease; D003091:Colistin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans; D010035:Otitis Media, Suppurative / Q000188:drug therapy*; D013752:Tetracycline / Q000627:therapeutic use*
chemical_list: D002701:Chloramphenicol; D013752:Tetracycline; D003091:Colistin